Mon, Jan 26, 2015, 2:12 AM EST - U.S. Markets open in 7 hrs 18 mins

Recent

% | $
Quotes you view appear here for quick access.

Cyclacel Pharmaceuticals, Inc. (CYCC) Message Board

  • mgs1066 mgs1066 Mar 2, 2013 5:43 PM Flag

    Boehringer Ingelheim vs. SAP and dacogen

    Boehringer Ingelheim:

    In a Phase II study reported last year, volasertib plus LDAC achieved an objective response in 31% of patients, significantly better than the 13% response rate seen with LDAC alone. Event-free survival (EFS) was also better with combination therapy at 5.6 months versus 2.3 months (The Pharma Letter December 12, 2012).

    SAP/ DAC

    Cyclacel Presents Updated Survival Data From the Pilot Study and Lead-In Phase of Seamless Phase 3 Study at the 2012 ASH Annual Meeting

    Median Overall Survival is 238 days, or Approximately 8 Months, and 1-Year Survival is 35% With an Overall Response Rate of 41% in Elderly Patients With Newly Diagnosed AML

    Forty-six patients were treated with alternating cycles of sapacitabine and decitabine, which is the treatment regimen in the experimental arm of SEAMLESS. Median age is 77 years (range 70-90). Thirty-three patients (72%) are 75 years or older. Median overall survival is 238 days, or approximately 8 months. The number of patients still alive at 3 months was 38 (83%), at 6 months 30 (65%), at 12 months 16 (35%) and at 18 months 12 (26%). Sixteen patients (35%) survived 1 year or longer. Among 33 patients who are 75 years or older, median overall survival is 263 days, or approximately 9 months, and 1-year survival is 36%. Nineteen patients (41%) responded with 10 complete responses (CRs), 4 partial responses (PRs) and 5 major hematological improvements (HIs). Median time to response is 2 cycles, i.e., one cycle of decitabine and one cycle of sapacitabine (range 1-10). Twenty-seven patients (59%) received 5 or more cycles of treatment. Two dose-limiting toxicities (DLT) were observed (lung infection/sepsis, typhlitis). Thirty-day mortality from all causes was 4%. Sixty-day mortality from all causes was 13% with one death from typhlitis considered to be possibly related to decitabine by investigator assessment. The sequential combination of decitabine and sapacitabine is safe and active.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
CYCC
0.61-0.03(-4.09%)Jan 23 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.